Rutgers Cancer Institute of New Jersey: Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment
January 29, 2021
January 29, 2021
NEW BRUNSWICK, New Jersey, Jan. 29 (TNSJou) -- Rutgers Cancer Institute of New Jersey issued the following news on Jan. 28, 2021:
Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this ra . . .
Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this ra . . .